15 Best and Cheap Stocks to Buy According to Billionaires

11. Bristol-Myers Squibb Company (NYSE:BMY)

Forward P/E Ratio: 8.88

No. of Billionaire Investors: 17

Bristol-Myers Squibb Company (NYSE:BMY) is a biopharmaceutical company that discovers, develops, and delivers advanced medicines for serious diseases. BMY’s medicines fall into various therapeutic classes, including hematology, oncology, cardiovascular, immunology, and neuroscience.

Bristol-Myers Squibb Company (NYSE:BMY) achieved double-digit revenue growth in 2024 reaching $48.30 billion. This was mainly driven by key products such as BREYANZI, Krazati, Reblozyl, and Opdivo. Reblozyl, a treatment for anemia patients, has rapidly grown to $1.7 billion in annual sales and is poised to expand further with additional trial results. In addition, BREYANZI has recently obtained approval from the European Commission (EC). This expanded approval applies to all EU member states as well as EEA countries including Iceland, Norway, and Liechtenstein. This expansion will further improve the company’s revenue in the years ahead.

Bristol-Myers Squibb Company has identified an additional $2 billion in savings, with $1 billion anticipated to be realized in 2025, improving financial flexibility. The company expects its 2025 revenue to be around $45.5 billion, driven by its growing portfolios in cardiology, hematology, and neuroscience.